Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00370370

Enrollment

Unknown

Registered

2006-08-31

Start date

2005-11-30

Completion date

Unknown

Last updated

2008-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular Age-Related Macular Degeneration

Keywords

Bevacizumab,, Triamcinolone, Age-related macular degeneration, Choroidal neovascular membrane

Brief summary

To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.

Interventions

DRUGbevacizumab

Injection of intravitreal bevacizumab

DRUGbevacizumab + triamcinolone acetonide

Injection of bevacizumab + triamcinolone acetonide

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Cases of active neovascular AMD with visual acuity of 20/400- 20/40

Exclusion criteria

* History of glaucoma or ocular hypertension * Disciform scar

Design outcomes

Primary

Measure	Time frame
visual acuity	—

Secondary

Measure	Time frame
central macular thickness	—
leakage in fluorescein angiography	—
intraocular pressure	—
anterior chamber reaction	—

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026